A patient with WHIM syndrome presenting relatively low TREC, KREC, and housekeeping gene levels by newborn screening -a case report and the literature review.

WHIM syndrome in a child without the classic tetrad: a case confirmed by de novo CXCR4 mutation.

Gene therapy via CRISPR/Cas9-mediated Cxcr4 disease allele inactivation reverses leukopenia in WHIM mice.

WHIM syndrome: from mechanism to targeted therapy - advances shaping clinical care.

CXCR4 antagonism corrects neutrophil abnormalities and reduces pneumonia severity in a pharmacological mouse model of CXCR2 loss-of-function-mediated neutropenia.

Case Report: A novel CXCR4 variant (p.S341Y) in a family with a pathogenic NFKB1 variant and variable clinical manifestations.

Immunoregulator multitasking in neurons is not just a WHIM.

Monoclonal gammopathy in WHIM syndrome can mask hypogammaglobulinemia.

Neurodevelopmental origins of structural and psychomotor defects in CXCR4-linked primary immunodeficiency.

Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024.

Continuous Infusion of the CXCR4 Antagonist Plerixafor for WHIM Syndrome.

Clinicopathologic Features and the Spectrum of Myelokathexis in Warts, Hypogammaglobulinemia, Infections, Myelokathexis Syndrome.

Mavorixafor: a CXCR4 antagonist for WHIM syndrome.

Mavorixafor, CXCR4 antagonist, a novel treatment for WHIM syndrome, first FDA approval 2024.

Cutaneous manifestations of WHIM syndrome.

Risk of Superficial Fungal Infections in WHIM Syndrome.

Recalcitrant tinea capitis in WHIM syndrome.

Unveiling WHIM syndrome: Mavorixafor's emerging role in immune restoration and therapy.

Corrigendum: Heterogeneous phenotype of a Chinese Familial WHIM syndrome with CXCR4V340fs gain-of-function mutation.

From phenotypic to molecular diagnosis: Insights from a clinical immunology service focused on inborn errors of immunity in Colombia.

CXCR4 antagonism ameliorates leukocyte abnormalities in a preclinical model of WHIM syndrome.

Heterogeneous phenotype of a Chinese Familial WHIM syndrome with CXCR4V340fs gain-of-function mutation.

Xolremdi (Mavorixafor): a breakthrough in WHIM syndrome treatment - unraveling efficacy and safety in a rare disease frontier.

Use of plerixafor for short-term management of leukopenia in a pediatric patient with WHIM syndrome.

CXCR4 signaling determines the fate of hematopoietic multipotent progenitors by stimulating mTOR activity and mitochondrial metabolism.

Increased Susceptibility of WHIM Mice to Papillomavirus-induced Disease is Dependent upon Immune Cell Dysfunction.

Expanding CXCR4 variant landscape in WHIM syndrome: integrating clinical and functional data for variant interpretation.

The complex nature of CXCR4 mutations in WHIM syndrome.

Unexpected diagnosis of WHIM syndrome in refractory autoimmune cytopenia.

Mavorixafor: First Approval.

Mavorixafor: a new hope for WHIM syndrome.

Plerixafor for pathogen-agnostic treatment in murine thigh infection and zebrafish sepsis.

A novel transmembrane CXCR4 variant that expands the WHIM genotype-phenotype paradigm.

CXCR4 chemokine antagonist scores a first FDA approval for WHIM syndrome.

A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome.

CXCR4 Antagonist in HPV5-Associated Perianal Squamous-Cell Carcinoma.

CXCR4 WHIM syndrome is a cancer predisposition condition for virus-induced malignancies.

Interplay between androgen and CXCR4 chemokine signaling in myelin repair.

Periodontal disease in patients with WHIM syndrome.

Congenital neutropenia: From lab bench to clinic bedside and back.

[Early detection of WHIM symdrome. A case report].

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.

Gene silencing on a WHIM.

Dale DC, Firkin F, Bolyard AA, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020;136(26):2994-3003.

Severe CD8+ T Lymphopenia in WHIM Syndrome Caused by Selective Sequestration in Primary Immune Organs.

Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review.

Historical Cohort of Severe Congenital Neutropenia in Iran: Clinical Course, Laboratory Evaluation, Treatment, and Survival.

WHIM Syndrome-linked CXCR4 mutations drive osteoporosis.

CRISPR/Cas9-mediated Cxcr4 disease allele inactivation for gene therapy in a mouse model of WHIM syndrome.

Reduced G protein signaling despite impaired internalization and β-arrestin recruitment in patients carrying a CXCR4Leu317fsX3 mutation causing WHIM syndrome.

WHIM Syndrome: First Reported Case in a Patient of African Ancestry.

[CXCR4 as a rheostat of humoral response].

Can we identify WHIM in infancy? Opportunities with the public newborn screening process.

Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency.

Dysregulated stem cell niches and altered lymphocyte recirculation cause B and T cell lymphopenia in WHIM syndrome.

Genotype-phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4WHIM variants.

Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients.

Clinical and Hematologic Effects of Endotoxin in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome Model Mice.

Altered CXCR4 dynamics at the cell membrane impairs directed cell migration in WHIM syndrome patients.

Case Report: A Novel CXCR4 Mutation in a Chinese Child With Kawasaki Disease Causing WHIM Syndrome.

A Sherlock Approach to a Kindred With a Variable Immunohematologic Phenotype.

Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?

Characterization of a new WHIM syndrome mutant reveals mechanistic differences in regulation of the chemokine receptor CXCR4.

Dexamethasone Treatment for COVID-19-Related Lung Injury in an Adult with WHIM Syndrome.

Mesenchymal Stem/Stromal Cells Overexpressing CXCR4R334X Revealed Enhanced Migration: A Lesson Learned from the Pathogenesis of WHIM Syndrome.

Multicenter Experience of Hematopoietic Stem Cell Transplantation in WHIM Syndrome.

Hematopoietic Multipotent Progenitors and Plasma Cells: Neighbors or Roommates in the Mouse Bone Marrow Ecosystem?

Unusual morphological abnormality of neutrophils in a patient with SARS-CoV-2 infection.

CXCR4 signaling controls dendritic cell location and activation at steady state and in inflammation.

Hematologic disorder-associated Cxcr4 gain-of-function mutation leads to uncontrolled extrafollicular immune response.

The negative charge of the 343 site is essential for maintaining physiological functions of CXCR4.

TREC Screening for WHIM Syndrome.

Hematopoietic Stem Cell Niches and Signals Controlling Immune Cell Development and Maintenance of Immunological Memory.

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.

Aberrant CXCR4 Signaling at Crossroad of WHIM Syndrome and Waldenstrom's Macroglobulinemia.

Incomplete Presentation of WHIM Syndrome: The Diagnostic Role of Dysmorphic Neutrophils in Bone Marrow.

CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent.

New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM.

Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice.

Family studies of warts, hypogammaglobulinemia, immunodeficiency, myelokathexis syndrome.

A chemotaxis model to explain WHIM neutrophil accumulation in the bone marrow of WHIM mouse model.

Abnormal Newborn Screen in a WHIM Syndrome Infant.

Acute myeloid leukemia arising after Hodgkin lymphoma in a patient with WHIM syndrome.

Case Report: Ocular toxoplasmosis in a WHIM syndrome immunodeficiency patient.

WHIM Syndrome: from Pathogenesis Towards Personalized Medicine and Cure.

Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4R334X.

The WHIM Syndrome Is No Longer a Whim.

Plerixafor for the Treatment of WHIM Syndrome. Reply.

Plerixafor for the Treatment of WHIM Syndrome.

Cerebellar involvement in warts Hypogammaglobulinemia immunodeficiency myelokathexis patients: neuroimaging and clinical findings.

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.

Acetate as a model for aspartate-based CXCR4 chemokine receptor binding of cobalt and nickel complexes of cross-bridged tetraazamacrocycles.

Long-Term Outcome of WHIM Syndrome in 18 Patients: High Risk of Lung Disease and HPV-Related Malignancies.

Rubella Virus-Associated Cutaneous Granulomatous Disease: a Unique Complication in Immune-Deficient Patients, Not Limited to DNA Repair Disorders.

Adaptive Immunodeficiency in WHIM Syndrome.

WHIM syndrome: Immunopathogenesis, treatment and cure strategies.

Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency.

Pathological roles of the homeostatic chemokine CXCL12.

Transient Marked Increase of γδ T Cells in WHIM Syndrome After Successful HSCT.

Enhancement of stem cell engraftment on a WHIM.

CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease.

Cxcr4-haploinsufficient bone marrow transplantation corrects leukopenia in an unconditioned WHIM syndrome model.

[Late diagnosis of WHIM sydrome].

Neutropenia, hypogammaglobulinemia, and pneumonia: A case of WHIM syndrome.

Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3.

Mechanisms of Sustained Neutrophilia in Patient WHIM-09, Cured of WHIM Syndrome by Chromothripsis.

How I treat warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

Pathogenesis, diagnosis and therapeutic strategies in WHIM syndrome immunodeficiency.

CXCL12 Mediates Aberrant Costimulation of B Lymphocytes in Warts, Hypogammaglobulinemia, Infections, Myelokathexis Immunodeficiency.

CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome.

WHIM Syndrome With a Novel CXCR4 Variant in a Korean Child.

Lymphoid differentiation of hematopoietic stem cells requires efficient Cxcr4 desensitization.

Dysplasia of Granulocytes in a Patient with HPV Disease, Recurrent Infections, and B Lymphopenia: A Novel Variant of WHIM Syndrome?

Preference of Genetic Diagnosis of CXCR4 Mutation Compared with Clinical Diagnosis of WHIM Syndrome.

G Protein-Coupled Receptor Kinase 3 and Protein Kinase C Phosphorylate the Distal C-Terminal Tail of the Chemokine Receptor CXCR4 and Mediate Recruitment of β-Arrestin.

Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.

Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders.

Efficient Plasma Cell Differentiation and Trafficking Require Cxcr4 Desensitization.

Modern management of phagocyte defects.

Successful hematopoietic stem cell transplantation for myelofibrosis in an adult with warts-hypogammaglobulinemia-immunodeficiency-myelokathexis syndrome.

Waldenström macroglobulinemia: biology, genetics, and therapy.

CXCR4 signaling in health and disease.

Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.

WHIM Syndrome Caused by Waldenström's Macroglobulinemia-Associated Mutation CXCR4 (L329fs).

Chromothriptic cure of WHIM syndrome: Implications for bone marrow transplantation.

Human Immunodeficiencies Related to Defective APC/T Cell Interaction.

Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.

Chromothriptic cure of WHIM syndrome.

Primary cutaneous follicle center lymphoma in a patient with WHIM syndrome.